Here's what we'll cover
Here's what we'll cover
What Bank of America's $250 Million GLP-1 Bill Tells Us
When a major corporation's CEO publicly announces that his company spends a quarter of a billion dollars a year on a single category of drugs, it's worth paying attention. Bank of America's CEO recently confirmed the company covers GLP-1 medications as part of its employee benefits package, to the tune of roughly $250 million annually.
That number is striking, but it reflects a broader reality: GLP-1 receptor agonists like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (found in Mounjaro) have become some of the most prescribed and most expensive drugs in the country.
For anyone currently taking or considering a GLP-1 medication, this headline is more than corporate news. It's a signal that the landscape for access and coverage is shifting, and understanding that shift can help you make smarter decisions about your own care.
Why Large Employers Are Betting on GLP-1 Coverage
It might seem counterintuitive for a company to voluntarily spend $250 million on a drug benefit. But from a corporate financial perspective, the math often works in their favor.
Obesity is linked to higher rates of type 2 diabetes, cardiovascular disease, sleep apnea, joint problems, and other costly chronic conditions. Employers who self-insure their health plans (meaning they pay claims directly rather than buying coverage from an insurer) absorb those costs directly. If GLP-1 medications reduce hospitalizations, surgeries, and long-term disease management costs, the investment can pay off.
Clinical data backs this reasoning. The SELECT trial, published in the New England Journal of Medicine in 2023, showed that semaglutide reduced major cardiovascular events by 20% in people with obesity who did not have diabetes. That kind of outcome matters to employers watching their healthcare spending.
What "Self-Insured" Means for Employees
Most large employers, including major banks and Fortune 500 companies, are self-insured. This means they design their own benefit plans, set their own formularies (the list of covered drugs), and decide which conditions qualify employees for coverage.
If your employer is self-insured and has chosen to cover GLP-1s, you may have access to these medications with relatively low out-of-pocket costs. If they haven't added GLP-1s to the formulary yet, your options through work may be limited regardless of what your plan documents say about "prescription coverage."
Does Your Employer Cover GLP-1 Medications?
Not every company has followed Bank of America's lead. In fact, coverage of GLP-1 drugs for weight loss (as opposed to type 2 diabetes management) remains inconsistent across employers and insurance plans.
Here's a general breakdown of where coverage tends to stand:
The best way to find out what your plan covers is to call the member services number on your insurance card and ask specifically whether semaglutide or tirzepatide is covered for obesity treatment (not just diabetes). Ask about prior authorization requirements and what BMI or diagnosis criteria apply.
What Coverage Criteria Usually Look Like
Even when an employer or insurer does cover GLP-1 medications for weight management, approval is rarely automatic. Most plans require you to meet specific criteria before they'll pay for the prescription.
Common requirements include:
- A BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol
- Documentation of prior attempts at weight loss through diet and exercise
- A prescription from a qualified provider, often with a documented diagnosis of obesity or overweight
- Periodic check-ins or evidence of progress to maintain coverage
These requirements exist because the drugs are expensive, and plans want to ensure they're being used appropriately. If you're denied coverage, you typically have the right to appeal. Your prescribing doctor can often help by providing supporting clinical documentation.
The Cost Gap Between Covered and Uncovered Patients
The financial difference between having GLP-1 coverage and not having it is significant. Brand-name GLP-1 medications without insurance can cost anywhere from $900 to over $1,300 per month depending on the drug and dose.
Patients without coverage face a stark choice: pay full price, seek compounded versions through licensed pharmacies, use manufacturer savings programs, or go without. None of those options are as simple as having an employer plan that covers the medication at a low copay.
What to Do If Your Employer Doesn't Cover GLP-1s
Not having employer coverage doesn't mean you're out of options. Many patients access GLP-1 medications through other pathways.
Manufacturer Savings Programs
Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) both offer savings programs for eligible commercially insured patients. Some programs reduce costs to as little as $25 per month, though eligibility and program terms change regularly.
Telehealth and Online Providers
A growing number of telehealth platforms prescribe GLP-1 medications and offer competitive pricing, sometimes including compounded semaglutide or tirzepatide at significantly lower costs. You can compare your options through our Best Providers page to find a service that fits your budget and medical needs.
Compounded Medications
When brand-name GLP-1 medications are in shortage, FDA-registered compounding pharmacies can legally produce compounded versions. These are not FDA-approved in the same way brand-name drugs are, but they offer a more accessible price point for many patients. The availability of compounded versions depends on current shortage status and state regulations.
GLP-1 Coupons and Savings Tools
Discount programs, coupon platforms, and pharmacy savings clubs can reduce costs for uninsured or underinsured patients. Check out our GLP-1 Coupons page for current savings options.
What This Corporate Trend Means for Future Access
Bank of America is not alone. According to benefits consulting surveys, a growing share of large employers added GLP-1 coverage for weight management in 2023 and 2024, and the trend appears to be continuing. That momentum creates pressure throughout the healthcare system.
When enough large employers cover a drug, pharmacy benefit managers (the middlemen who negotiate drug prices for insurers) gain more data on utilization and outcomes. That data can eventually influence what smaller employers and government payers decide to cover.
There's also a political and regulatory dimension. The FDA's approval of Wegovy for cardiovascular risk reduction in 2024 opened the door for Medicare to cover it in specific circumstances, something that was previously prohibited. Each expansion of coverage at the employer or government level makes it slightly harder for other payers to justify exclusions.
This doesn't mean everyone will have access soon. Cost remains a genuine barrier. But the trajectory, driven partly by high-profile employer commitments like Bank of America's, points toward broader access over time.
Questions to Ask Your HR Department and Doctor
If you're interested in starting a GLP-1 medication and want to understand your coverage, here are specific questions worth asking.
Ask your HR or benefits team:
- Is semaglutide or tirzepatide covered under our plan for weight management?
- What diagnosis or BMI criteria do I need to meet?
- Is prior authorization required, and how long does it take?
- Which pharmacies are in-network for specialty medications?
Ask your doctor or provider:
- Am I a candidate for a GLP-1 medication based on my current health?
- Can you document my medical history in a way that supports insurance approval?
- If my insurance denies the claim, would you support an appeal?
- Are there alternative medications or doses that might be more affordable under my plan?
Having these conversations before you fill your first prescription can save you from unexpected costs and delays.
No waiting list. No insurance needed.
Frequently Asked Questions
Does insurance cover GLP-1 medications like Ozempic or Wegovy?
Coverage varies widely by plan and employer. Many large employer plans now cover GLP-1 drugs for weight management, but smaller plans and government programs like Medicare and Medicaid have more restrictions. Always call your insurer directly to ask whether semaglutide or tirzepatide is covered for obesity treatment.
How much do GLP-1 drugs cost without insurance?
Without insurance, brand-name GLP-1 medications typically cost between $900 and $1,300 per month. Compounded versions from licensed pharmacies can cost significantly less, often between $150 and $500 per month, though availability depends on shortage status and state regulations.
Why are employers covering GLP-1 medications?
Large employers, especially those that self-insure their health benefits, often find that covering GLP-1 medications can reduce long-term costs tied to obesity-related conditions like cardiovascular disease and type 2 diabetes. Clinical trials have shown meaningful reductions in serious health events for people taking semaglutide, which can translate to lower healthcare spending over time.
What BMI do you need to qualify for a GLP-1 prescription?
Most coverage criteria and clinical guidelines require a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes. Your provider can confirm what applies to your specific situation.
Can I get a GLP-1 medication through telehealth if my employer doesn't cover it?
Yes. Many telehealth platforms offer GLP-1 prescriptions and work with pharmacies to provide competitive pricing. Some services offer compounded semaglutide or tirzepatide at lower costs than brand-name versions. Comparing providers can help you find the most affordable and medically appropriate option.
What is compounded semaglutide and is it safe?
Compounded semaglutide is a version of the active ingredient in Ozempic and Wegovy made by a licensed compounding pharmacy. It is not FDA-approved as a finished drug product, but it can be legally produced when the brand-name drug is on the FDA shortage list. Quality and safety depend on the pharmacy's standards, so working with a reputable, FDA-registered compounding pharmacy is important.
The Bottom Line: What This Means for Your Access and Your Wallet
Bank of America's $250 million GLP-1 budget is a headline, but what it really represents is a widening gap between patients who have access to these medications through generous employer coverage and those who don't.
If you work for a large company, now is a good time to review your benefits and have a direct conversation with your HR team about GLP-1 coverage. If your plan covers these medications and you meet the criteria, you may be closer to access than you think.
If your employer doesn't cover GLP-1 medications, or if you're self-employed or uninsured, the path is more complicated but not closed. Manufacturer savings programs, telehealth providers with competitive pricing, compounded medication options, and third-party discount programs all represent real alternatives worth exploring.
The cost of these medications is a legitimate barrier, and it's one that advocates, employers, and policymakers are increasingly aware of. Progress on broader coverage is happening, though unevenly. In the meantime, being informed and proactive is your best tool.
Whatever your situation, speak with a licensed medical provider before starting or changing any GLP-1 medication. The right drug, dose, and provider relationship matters as much as the cost.
If you're ready to take the next step, GLP-1.com can help. Browse our Best Providers comparison to find a telehealth platform that fits your budget, or check the GLP-1 Coupons page for current savings on brand-name and compounded options. You can also learn more about specific medications like Wegovy, Ozempic, and Mounjaro to understand which might be right for your health goals.